pocketful logo light
pocketful logo light
Piramal Pharma Ltd logo

Piramal Pharma Ltd

NSE: PPLPHARMA BSE: 543635

₹158.90

(0.81%)

Wed, 24 Jun 2026, 08:01 am

mtf coin illustrationMTF 5x

Piramal Pharma Share Price Live Chart

1 Day

(0.81%)

No Result Found

Summary

  • Market Cap (in Cr)

    22916.24

  • Net Profit (in Cr)

    91.13

  • P/B

    3.66

  • Sector P/E

    33.76

  • P/E

    325.36

  • EV/EBITDA

    20.63

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    1.14

  • ROCE

    6.43

  • Debt/Equity

    0.60

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    61.42

  • Interest Cover

    1.98

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters34.8634.8634.8634.8634.95
FII30.1829.6630.2730.8631.49
DII15.6115.6914.8914.2614.78
Public19.3519.8019.9820.0218.78
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

54.96

MACD

-1.04

50 DMA

166.45

200 DMA

172.98

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic253.01214.34193.56175.67154.89137.0098.33
Fibonacci214.34199.56190.44175.67160.89151.77137.00
Camarilla183.42179.88176.33175.67169.25165.70162.16

Pivots Level: Classic

R3

+77.34

253.01

R2

+38.67

214.34

R1

+17.90

193.56

175.67
175.67
Pivot Point
LTP: 169.83

S1

-20.77

154.89

S2

-38.67

137.00

S3

-77.34

98.33

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    164.91

  • 20-EMA

    165.94

  • 30-EMA

    166.07

  • 50-EMA

    165.00

  • 100-EMA

    165.13

  • 200-EMA

    171.99

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
28 Apr 2026board-meetingsAccounts, Quarterly Results
28 Jan 2026board-meetingsQuarterly Results
05 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
16 Jun 2025dividendFinal Dividend - Rs. - 0.1416 Jul 2025
13 Jun 2025agm
14 May 2025dividend₹0.14 Dividend /Share16 Jul 2025
12 Jun 2024dividendFinal Dividend - Rs. - 0.1112 Jul 2024
11 Jun 2024agm
10 May 2024dividend₹0.11 Dividend /Share12 Jul 2024
27 Jul 2023rights5:46 Rights Issue of Equity Shares02 Aug 2023

Read More

Peer Comparison

Piramal Pharma Ltd logo

Piramal Pharma Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Piramal Pharma Ltd About

Piramal Pharma is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. We operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (“CDMO”) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (“APIs”), Finished dosage forms (“FDFs”), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (“CHG“) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and Piramal Consumer Healthcare (“PCH“) business, selling well-known OTC brands.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2020

Headquarters

CEO

Nandini Piramal

Employees

Contact

Website icon

Website

http://www.piramalpharma.com

Email icon

Email

corporate.secretarial@piramal.com

Phone icon

Phone

Location icon

Location

Ananta Bldg Piramal Corporate, Park LBS Marg Kurla west, Mumbai, Maharashtra, 400070

Read More

Piramal Pharma Ltd Company History

YearHistory
2020
  • The company was incorporated on March 4, 2020 at Mumbai as a public limited company.
  • The company acquired the pharmaceutical business from PEL.
  • The company received a 20% Strategic Growth Investment by Carlyle.
  • The company increased its stake to 100% in CCPL.
  • Piramal Pharma and Navin Fluorine mutually agreed on Piramal increasing its stake to 100% in Convergence Chemicals.
  • Piramal Pharma Solutions collaborated with Epirium Bio on an exclusive integrated development and manufacturing program for orphan drugs.
  • Piramal Pharma Solutions announced an integrated development program with Bolt Biotherapeutics for immune-stimulating antibody conjugates and sterile fill-finish.
  • Piramal Critical Care announced a strategic partnership with US-based pharmaceutical outsourcing facility Medivant Healthcare.
2021
  • The company acquired HPPL.
  • Piramal Pharma Solutions announced the winner of its Inaugural Award for Excellence in Patient Centricity.
  • Piramal Pharma Solutions entered into a Master Services Agreement with Plus Therapeutics, Inc.
  • Piramal Pharma Limited's Consumer Products Division launched 'i-feel'.
2022
  • The company acquired a minority stake in Yapan Bio Private Limited.
  • The Composite Scheme of Arrangement was sanctioned by the NCLT on August 12, 2022.
  • Piramal Pharma Solutions announced the winner of its September 2022 Award for Excellence in Patient Centricity.
  • Piramal Pharma Solutions launched ADCelerate, a rapid, integrated approach to taking ADCs to IND.
  • Piramal Pharma Solutions held the grand opening ceremony for its new API plant at Aurora, Canada manufacturing site.
  • Piramal Pharma Solutions' new API plant in Canada went online and initial production runs were successfully completed.
2023
  • The company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkBuy6856958219.720 Feb 2025
GRAVITON RESEARCH CAPITAL LLPbulkSell6856958219.8820 Feb 2025
EAST BRIDGE CAPITAL MASTER FUND LIMITEDblockSell33643099102.831 Oct 2023
EAST BRIDGE CAPITAL MASTER FUND I LIMITEDbulkBuy33643099102.831 Oct 2023
EAST BRIDGE CAPITAL MASTER FUND LIMITEDbulkSell33643099102.831 Oct 2023
EAST BRIDGE CAPITAL MASTER FUND I LIMITEDblockBuy33643099102.831 Oct 2023
CAISSE DE DEPOT ET PLACEMENT DU QUEBECbulkSell1057046694.4816 Jun 2023
THE VANGUARD GROUP INC AC VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUNDbulkBuy620291294.7116 Jun 2023
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell4050700166.9503 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy4050700166.9503 Nov 2022

Read More

Piramal Pharma Ltd News

Piramal Pharma schedules 6th AGM for July 30

Piramal Pharma Limited will hold its 6th Annual General Meeting on July 30, 2026, via video conferencing. The meeting was announced in a regulatory filing.

19 Jun 2026

companies

Piramal Pharma: ₹59.13 Cr Block Trade on NSE

Piramal Pharma sees a block trade of ~3,515,258 shares on NSE at ₹168.22 per share, aggregating to ₹59.13 crores.

15 Jun 2026

equity-markets

Piramal Pharma Eyes Niche Peptides, Sidesteps GLP-1 Race

Piramal Pharma says it will avoid competing in the crowded GLP-1 segment during the global surge, instead focusing on unique peptides with dedicated markets.

15 Jun 2026

companies

GPCB Permanently Lifts Closure Orders for Piramal Pharma's Dahej Facility

Piramal Pharma's Dahej facility has had its closure orders permanently lifted by GPCB, allowing normal operations to resume with a continued focus on environmental compliance.

03 Jun 2026

companies

Piramal Pharma schedules investor meets

Piramal Pharma will hold analyst meetings from June 9-11, 2026. The sessions include physical and virtual interactions with Macquarie, Motilal Oswal, and Choice Institutional.

01 Jun 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number